Vaccines Pipeline

Vaccine Late-Stage Hits and Misses, 2024 to 2026

CMV Phase 3 miss, norovirus interim analysis short of early-success criteria, mFLUSIVA approval, Capvaxive launch, and intismeran still the oncology option.

Oct 2025

Asset:
mRNA-1647 CMV
Company:
Moderna
Result:
Phase 3 miss
Note:
6% to 23% efficacy. Congenital program discontinued.

2026

Asset:
mRNA-1403 norovirus
Company:
Moderna
Result:
Phase 3 interim analysis
Note:
Did not meet statistical criteria for early success. Trial ongoing and blinded; additional cohort planned.

5 Aug 2026

Asset:
mFLUSIVA (mRNA-1010)
Company:
Moderna
Result:
FDA approved, adults 50+
Note:
First US mRNA flu shot. Study P304 relative vaccine efficacy 26.6% (95% CI 16.7 to 35.4) vs standard-dose for RT-PCR-confirmed influenza-like illness in adults 50+ (411 vs 557 cases). ACIP and contracting still pending for 2026-27 volume.

19 Aug 2026

Asset:
Intismeran autogene + Keytruda (INTerpath-001)
Company:
Moderna / Merck
Result:
Phase 3 melanoma hit (RFS, DMFS)
Note:
Met RFS (primary) and DMFS (key secondary) vs Keytruda alone in 1,137 resected stage IIB-IV patients (2:1). Detail released 22 Oct 2026 ahead of ESMO LBA1: RFS HR 0.58 (95% CI 0.45 to 0.75; 42% lower risk of recurrence or death) and DMFS HR 0.62 (95% CI 0.45 to 0.85), median follow-up 24.6 months. OS not yet mature; companies say they are engaging regulators. Phase 2b five-year: 49% cut in recurrence or death vs Keytruda alone.

2024-2025

Asset:
Capvaxive
Company:
Merck
Result:
Launch hit
Note:
$759M in first full year. Adult pneumococcal share taker versus Prevnar.

Jun 2025

Asset:
Enflonsia (clesrovimab)
Company:
Merck
Result:
FDA approved
Note:
Infant RSV mAb. Sales not yet a disclosed franchise line.

Named Shots After Congenital CMV

Lyme VALOR (statistical miss, Pfizer still filing), Qdenga commercial, CMV transplant Phase 2 still on, HEPLISAV-B nine-month sales. Not respiratory, not intismeran.

LB6V (formerly VLA15) Lyme

Company:
Pfizer / Valneva
Status:
Phase 3 VALOR. EMA validated the EU marketing authorization application on 14 Aug 2026 and began its assessment; Pfizer planned submissions (23 Mar 2026 PR)
Printed mark:
73.2% reduction in confirmed Lyme vs placebo from 28 days post-dose 4 (95% CI 15.8, 93.5). The pre-set criterion (CI lower bound above 20) was not met in the first pre-specified analysis because fewer cases accrued than planned. Second analysis lower bound was above 20.

Qdenga dengue

Company:
Takeda
Status:
Commercial. WHO prequalified. Available in more than 30 countries per the FY2025 presentation
Printed mark:
JPY 40.8B sales in FY2025 (year ended 31 Mar 2026), +10.7% CER. Plan to manufacture 21 million doses in FY2026.

mRNA-1647 congenital CMV

Company:
Moderna
Status:
Discontinued October 2025
Printed mark:
Phase 3 (NCT05085366) did not meet the primary endpoint. Vaccine efficacy 6% to 23% depending on case definition. Not a remaining commercial bet.

mRNA-1647 CMV in HCT

Company:
Moderna
Status:
Phase 2 ongoing
Printed mark:
NCT05683457. ClinicalTrials.gov: active, not recruiting. Actual enrollment 84. No efficacy print. Do not treat congenital discontinuation as a transplant readout.

HEPLISAV-B adult HepB

Company:
Dynavax / Sanofi
Status:
Commercial. Sanofi completed its Dynavax acquisition on 10 Feb 2026 (agreement dated 23 Dec 2025, announced 24 Dec 2025)
Printed mark:
9M 2025 net product revenue $246.8M (Dynavax Q3 2025). FY 2025 is not taken from a 10-K here. Not a peak-sales model.

Z-1018 shingles

Company:
Sanofi / Dynavax
Status:
Pipeline challenger inside the Dynavax deal
Printed mark:
No 2026 US commercial competitor to Shingrix. Long-dated. No Phase 3 efficacy number printed for a 2026 launch.

Personalized Cancer Vaccine Trials

Intismeran autogene with Merck versus BioNTech iNeST. Option-value, not 2026 product revenue.

Intismeran autogene (mRNA-4157 / V940) + Keytruda

Company:
Moderna / Merck
Setting:
Adjuvant melanoma; other tumors in INTerpath
Evidence:
Phase 3 INTerpath-001 (topline 19 Aug 2026, detail 22 Oct 2026): at the primary pre-specified analysis (intention-to-treat, median follow-up 24.6 months) the combination cut the risk of recurrence or death by 42% (RFS, HR 0.58, 95% CI 0.45 to 0.75, p<0.001) and of distant metastasis or death by 38% (DMFS, HR 0.62, 95% CI 0.45 to 0.85, p=0.002) vs Keytruda alone; OS not yet mature. Phase 2b five-year: 49% reduction in recurrence or death vs Keytruda alone
2026 commercial:
No 2026 product revenue. Phase 3 melanoma is the filing gate; the companies say they are engaging with regulatory authorities, with no filing date given.

iNeST individualized neoantigen

Company:
BioNTech / Genentech
Setting:
Solid tumors
Evidence:
Colorectal Phase 2 (BNT122-01, vs watchful waiting) terminated 28 Aug 2026 after a DSMB-noted numerical imbalance in overall survival. Pancreatic Phase 2 (IMcode003) continues
2026 commercial:
BioNTech guided no oncology product revenue in 2026. Vaccines are the cash residual.

Pumitamig (PD-L1/VEGF-A) + BMS

Company:
BioNTech / BMS
Setting:
Not a vaccine
Evidence:
€613M collaboration revenue recognized in Q3 2025
2026 commercial:
Shown so readers do not confuse BMS collab cash with Comirnaty.

Vaccine CBER and EMA Decision Calendar

Dates that can move MRNA, GSK, SNY, PFE, and BNTX. ACIP still sits after FDA for coverage.

5 Aug 2026

Asset:
mFLUSIVA
Agency:
FDA
Status:
Approved, adults 50+ (65+ under accelerated approval, continued approval may depend on a confirmatory trial)
Why it moves the stock:
Unlocks mRNA flu and the combo path. Volume still needs ACIP.

19 Aug 2026

Asset:
Intismeran Phase 3 melanoma
Agency:
FDA path TBD
Status:
Phase 3 met RFS and DMFS (RFS HR 0.58, 95% CI 0.45 to 0.75); companies say they are engaging regulators, no filing date given
Why it moves the stock:
Largest remaining mRNA option after the CMV Phase 3 miss and norovirus missing early-success criteria at its interim analysis. Detailed results released 22 Oct 2026 ahead of ESMO (23-27 Oct).

27 Aug 2026

Asset:
Comirnaty, Spikevax, mNEXSPIKE (2026-27 XFG formula)
Agency:
FDA
Status:
Approved. 65+ and high-risk younger people: Comirnaty from age 5, mNEXSPIKE from 12, Spikevax from 6 months. Nuvaxovid XFG: FDA page lists a 27 Aug 2026 approval letter (65+ and 12 to 64 high-risk), Novavax release 28 Aug
Why it moves the stock:
Seasonal COVID revenue for PFE, BNTX, MRNA and NVAX. FDA product pages list approval letters dated 27 Aug 2026.

23 Sep 2026

Asset:
2026-27 COVID-19 vaccines
Agency:
CDC
Status:
Recommended for all adults 18+; children 6 months to 17 years: recommended if moderately or severely immunocompromised, otherwise shared decision-making
Why it moves the stock:
CDC clinical considerations page updated 23 Sep 2026. Use in ages under 65 without a high-risk condition is off-label.

2026-27 season

Asset:
mFLUSIVA ACIP
Agency:
CDC ACIP
Status:
No vote: CDC lists all three 2026 ACIP meetings (18-19 Mar, 24-26 Jun, 21-23 Oct) as cancelled due to ongoing litigation
Why it moves the stock:
Coverage and VFC/Medicare follow the vote, not the FDA letter.

9 Jul 2026

Asset:
mRESVIA EC joint procurement
Agency:
EC
Status:
Framework contract signed, announced by the EC 9 Jul 2026: up to 24M doses, six countries, no minimum purchase, up to four years
Why it moves the stock:
Public-sector RSV volume in six countries, but with no minimum purchase.

10 Feb 2026

Asset:
Sanofi-Dynavax close
Agency:
Deal / HSR
Status:
Completed 10 Feb 2026: tender offer at $15.50 a share (~$2.2B equity value, announced 24 Dec 2025) closed with 73.92% of shares tendered
Why it moves the stock:
HEPLISAV-B plus a shingles candidate (Z-1018, Phase 1/2). Dynavax 8-K of 10 Feb 2026 confirms the tender completed.

Vaccine M&A and Licensing, 2023 to 2026

CureVac, Dynavax, Matrix-M, Icosavax, and the Bavarian-Serum Institute chikungunya transfer.

11 Dec 2023
DealAstraZeneca

AstraZeneca agrees to acquire Icosavax: $15.00 a share in cash plus a CVR of up to $5.00, about $838M upfront and up to $1.1B in equity value

Adds IVX-A12, a virus-like-particle vaccine candidate against RSV and hMPV in older adults. Merger agreement dated 11 Dec 2023; acquisition completed 19 Feb 2024.

18 Dec 2025
DealBioNTech

BioNTech closes its CureVac exchange offer, about 86.75% of shares tendered

Per BioNTech, complements its mRNA design, delivery formulation and manufacturing capabilities. Compulsory acquisition of the remaining shares completed at the beginning of January 2026.

24 Dec 2025
DealSanofi

Sanofi agrees to buy Dynavax at $15.50 a share, about $2.2B

Adds HEPLISAV-B, a marketed adult hepatitis B vaccine, and the Phase 1/2 shingles candidate Z-1018. Agreement dated 23 Dec 2025; tender offer and merger completed 10 Feb 2026.

15 Jan 2026
DealNovavax / Pfizer

Novavax grants Pfizer a non-exclusive worldwide Matrix-M adjuvant license for one infectious disease, with a second at Pfizer's option

$30M upfront and up to $500M in milestones across both fields, plus tiered high mid-single-digit percentage royalties. Agreement dated 15 Jan 2026.

11 Mar 2026
DealBavarian Nordic

Bavarian Nordic and Serum Institute of India sign a chikungunya vaccine contract manufacturing agreement

Full tech transfer of the chikungunya vaccine (CHIKV VLP) for future supply to endemic low- and middle-income countries; it replaces the agreement previously entered with Biological E.

Disclosed Pipeline by Pathogen

Issuer programs only, not a Citeline census. After CMV, the map is respiratory plus one oncology option.

COVID

What is left:
Seasonal updates plus combos
Lead names:
Pfizer/BioNTech, Moderna, Sanofi/Novavax
Status:
Commercial. APA world is over.

Flu

What is left:
mRNA vs egg/cell/recombinant
Lead names:
Sanofi, Seqirus, GSK, Moderna mFLUSIVA
Status:
mFLUSIVA approved Aug 2026; ACIP pending. GSK mRNA flu (HA plus NA): positive Phase 2, Phase 3 efficacy trial planned to start Sep 2026.

RSV adult

What is left:
Share fight, not a new TAM
Lead names:
Arexvy, Abrysvo, mRESVIA
Status:
Single-dose ACIP. Combos are the next attempt to grow visits.

RSV infant

What is left:
mAb vs maternal vaccine
Lead names:
Beyfortus, Enflonsia, maternal Abrysvo
Status:
Beyfortus is the disclosed P&L.

CMV

What is left:
Mostly dead as a congenital mRNA bet
Lead names:
Moderna discontinued
Status:
Phase 3 miss Oct 2025.

Norovirus

What is left:
Retry
Lead names:
Moderna mRNA-1403
Status:
Phase 3 interim analysis did not meet early-success criteria (31 Jul 2026); trial continues.

HPV

What is left:
No near-term branded US challenger
Lead names:
Gardasil 9; SII Cervavac in LMIC
Status:
Country risk, not pipeline risk.

Shingles

What is left:
Long-dated challenger
Lead names:
Shingrix; Sanofi-Dynavax Z-1018
Status:
No 2026 US competitor.

Pneumococcal

What is left:
Valency race
Lead names:
Prevnar 20, Capvaxive, Vaxneuvance
Status:
Adult share fight is commercial, not Phase 3.

Oncology

What is left:
Personalized mRNA + checkpoint
Lead names:
Intismeran; BioNTech iNeST
Status:
Intismeran Phase 3 melanoma met RFS and DMFS (19 Aug 2026). iNeST colorectal Phase 2 terminated (28 Aug 2026). Option-value. No 2026 product revenue guided.

Adjuvant and Platform Bets

AS01, Matrix-M, CpG 1018, LNP IP, sa-mRNA, and protein/VLP. Who captures the next respiratory or endemic dollar.

AS01 adjuvant

Owner:
GSK
Where it shows up:
Shingrix, Arexvy
Equity angle:
Moat on the two biggest GSK vaccines. Not licensed out cheaply.

Matrix-M

Owner:
Novavax; licensed to Pfizer Jan 2026
Where it shows up:
Nuvaxovid; future Pfizer programs
Equity angle:
Turns NVAX into an adjuvant royalty plus a shrinking COVID P&L.

CpG 1018

Owner:
Dynavax / Sanofi (closed 10 Feb 2026)
Where it shows up:
HEPLISAV-B; shingles candidate Z-1018
Equity angle:
The Dynavax deal is an adjuvant and hepatitis B franchise, and a Shingrix shot across the bow.

LNP / Acuitas IP

Owner:
Acuitas (private) plus sponsors
Where it shows up:
Comirnaty, Spikevax, mRESVIA, mFLUSIVA
Equity angle:
IP and lipid supply, not a public pure-play in this roster.

sa-mRNA

Owner:
Arcturus; CSL Seqirus interest
Where it shows up:
Kostaive COVID in Japan
Equity angle:
Self-amplifying. Small-cap (ARCT), not a US seasonal franchise in 2026.

Protein / VLP

Owner:
Pfizer, GSK, Merck, Novavax, Sanofi
Where it shows up:
Abrysvo, Arexvy, Gardasil, Nuvaxovid
Equity angle:
Still most of the branded dollars.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Vaccines Pipeline: Market Data | Sterling